MPLT MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. (MPLT) is confirmed to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $1.15 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MapLight Therapeutics, Inc.
MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company's lead product candidate includes ML-007C-MA. MapLight Therapeutics Inc. is based in SAN FRANCISCO.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.